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Abstract 
 
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by tissue accumulation of 
CD1a
+
 CD207
+
 LCH cells. In LCH, somatic mutations of the BRAF
V600E
 gene have been detected in 
tissue LCH cells, bone marrow CD34
+
 hematopoietic stem cells, circulating CD14
+
 monocytes, and 
BDCA1
+
 myeloid DCs. Targeting BRAF
V600E
 in clonal LCs and their precursors is a potential 
treatment option for patients whose tumors have the mutation. The development of mouse 
macrophages and LCs is regulated by the CSF-1 receptor (CSF1R). In patients with diffuse-type 
tenosynovial giant cell tumors, CSF1R inhibition depletes tumor-associated macrophages (TAMs) 
with therapeutic efficacy; however, CSF1R signaling in LCs and LCH has not been investigated. 
We found through immunohistochemistry and flow cytometry that CSF1R is normally expressed on 
human CD1a
+
CD207
+
 LCs in the epidermis and stratified epithelia. LCs that were differentiated 
from CD14
+
 monocytes, BDCA1
+
 DCs, and CD34
+
 cord blood progenitors expressed CSF1R that 
was downregulated upon maturation. Immature LCs migrated toward CSF1, but not IL34. 
Administration of the c-FMS/CSF1R kinase inhibitors GW2580 and BLZ945 significantly reduced 
human LC migration. In LCH clinical samples, LCH cells (including BRAF
V600E
 cells) and TAMs 
retained high expression of CSF1R. We also detected presence of transcripts for its ligand, CSF1, 
but not IL34, in all tested LCH cases. CSF1R and CSF-1 expression in LCH, and their role in LC 
migration and differentiation, suggests CSF1R signaling blockade as a candidate rational approach 
for treatment of LCH, including the BRAF
V600E
 and wild-type forms of the disease. 
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INTRODUCTION 
Langerhans cell histiocytosis (LCH) is characterized by tissue accumulation of transformed cells 
with features of Langerhans cells (LC) (1). LCH occurs in children and adults, and ranges from a 
single site lesion to systemic forms (2). The diagnosis is based on radiological presentation 
combined with tissue infiltration of LCs identified by CD1a, CD207, and S100 protein. MAPK 
activation is recurrent in LCH due to somatic mutations of components of the pathway (3). The 
identification of BRAFV600E with a mutation-specific antibody allows the confirmation of the clonal 
identity of most tissue-infiltrating LCs in LCH (4). BRAFV600E is also detected in CD34+ 
hematopoietic progenitors, circulating CD11c+CD14+ precursors (5,6), BDCA1+ myeloid DCs, and 
CD16+ non-classical monocytes, suggesting the presence of BRAF-mutated LCH cases within the 
group of myeloid neoplasia (5,6). 
 
This new paradigm shift in the LCH pathogenesis predicts that clonal circulating precursors are 
driven to terminal LCs differentiation by the tissue cytokine milieu. In this context, CSF1R 
signaling via its cognate ligands CSF-1 and IL34 plays a relevant role in various biological 
processes leading to differentiation of monocyte-derived cells, particularly macrophages. 
Accordingly, CSF1R blockade has been proposed (7) as a therapeutic strategy in various cancers, 
with more than twenty recruiting clinical trials existing 
(https://clinicaltrials.gov/ct2/results?recrs=ab&cond=Cancer&term=csf1r&cntry=&state=&city=&d
ist=) that employ this strategy. Among available compounds, the RG7155/emactuzumab, a specific 
CSF1R humanized antibody, has been shown to deplete CSF1R-expressing tumor-associated 
macrophages in advanced cancer patients (7). In addition to macrophages, RG7155/emactuzumab 
depletes blood CD16+, but not CD14+, monocytes (7), which is consistent with their higher 
expression of surface CSF1R (7,8). 
 
Although the role of CSF-1 in human DCs has been partially characterized (9,10), the effects of 
CSF1R blockade on DC subsets are poorly understood. In mice, LCs are tightly dependent on 
CSF1R signaling for their development and maintenance (9). Mouse CSF1R binds CSF-1 and IL34, 
the latter being able to promote LC differentiation and maintenance in adulthood (10,11). In 
humans, CSF1R is expressed on DC progenitors and monocyte-derived DCs (8,12,13), whereas 
circulating and tissue conventional myeloid DCs are negative for CSF1R expression (8,14) and are 
not dependent on CSF1R for their development (15). High serum concentration of CSF-1 has been 
detected in LCH, particularly in the systemic forms (16,17). In addition, activating mutations in 
CSF1R have been identified in histiocytic neoplasm (18). However, CSF1R expression and 
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signaling involvement in human LCs and LCH has not been addressed. 
In this study, we found that CSF1R was expressed in immature human CD207+ LCs, whereas it was 
lost upon LC maturation, as well as in nodal interdigitating DCs. CSF1R engaged by CSF1, but not 
IL34, provided a effective chemotactic signal to LCs. In addition, CSF1R blockade impaired LC 
differentiation from hematopoietic precursors. LCH cells and tumor-associated macrophages 
retained CSF1R, as verified in clinical samples. Together, these findings suggest CSF1R blockade 
as a candidate for the treatment of LCH. 
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METHODS 
 
 
Tissue and immunohistochemistry 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from normal skin (n=5), lung (n=2), 
esophagus (n=2), cervix (n=2), tonsils (n=2), reactive lymph nodes (n=2), dermatopatic 
lymphadenitis (n=12), as well as pathological tissues including Langerhans cell histiocytosis 
(n=54), cutaneous squamous cells carcinoma (n=5), primary cutaneous melanoma (n=9), and 
mycosis fungoides (n=3) were used. Cases were retrieved from the tissue archive of the Department 
of Pathology, ASST Spedali Civili di Brescia (Italy) and from Azienda Ospedaliero Universitaria, 
Modena (Italy). LCH cases inclusion criteria were expression of CD207 and CD1a in the majority 
of neoplastic cells. The study has been conducted according to the Declaration of Helsinki and 
approved by the local ethic board (NP906- WV-IMMUNOCANCERhum). Four-micrometer-thick 
tissue sections were used for immunohistochemical staining. Immunohistochemistry was performed 
after appropriate antigen retrieval (40’ in thermostatic waterbath in EDTA buffer pH8.0 for CSF1R 
and BDCA1) using antibodies reported in Supplementary Table S1. Single immune reactions were 
developed using NovolinkTM Polymer Detection System (cat. no. RE7280-K, Leica Biosystems, 
NewCastle upon Tyne, UK). For double/triple immunohistochemistry, the second immune reaction 
was visualized using Mach 4 Universal AP-Polymer Kit (cat. no. M4U536L, Biocare Medical, 
Concord, CA) followed by Ferangi Blue (cat. no. FB813S, Biocare Medical); sequentially the third 
immune reaction was visualized using Dako REAL™ Detection System, Alkaline 
Phosphatase/RED (cat. no. K5005, Dako, Glostrup, Denmark). BRAF (VE1) was stained by 
BenchMark ULTRA IHC/ISH system (cat. no 05342716001, Roche Diagnostics). 
 
LCs purification from human skin. 
Primary LCs and dermal DCs were purified from normal human skin (n=10) obtained as discarded 
material from reduction abdominoplasty after written consent, according to a protocol approved by 
the CTO/Città della Salute e della Scienza Hospital Ethical Board (Torino, Italy) and in adherence 
with the Declaration of Helsinki Principles. Following excision of subcutaneous fat, skin was cut in 
strips and exposed to dispase. Briefly, the skin was digested with 1U/ml dispase (cat. no. 17105041, 
Thermo Fisher Scientific, Waltham, MA), and penicillin-streptomycin solution overnight at 37°C, 
and the epidermis was peeled off the dermis. Dermal and epidermal sheets were then incubated 
separately in media containing 1% FBS (cat. no. 10270-106, Thermo Fisher Scientific), 200U/ml 
collagenase (cat. no. C5138) and 100U/ml DNase I (cat. no. 10104159001) (Sigma-Aldrich, Milan, 
Italy) at 37°C in a rotator for 30 min and 2 h, respectively. The cells were then separated using a tea 
Lonardi et al. 
7 
 
 
strainer (700 m mesh size) and the supernatants were then passed through a 100 m cell strainer 
for two times. For epidermal suspension, cells were spun at 400 g for 30 min on a Ficoll-Paque 
PLUS (cat. no. GE17-1440-02, GE Healthcare Bio- Sciences, Sigma-Aldrich) gradient and the 
immune cells harvested. Dermal cells were enriched for 
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CD45 expressing cells using magnetic beads (cat. no.130-045-801, Miltenyi, Bergisch Gladbach, 
Germany). Cells were then counted and labeled for flow cytometric evaluation of surface 
expression markers. In some experiments, cells enriched for CD45 (containing LCs) from the 
epidermis were left untreated or stimulated for 48 h with LPS (1 ug/ml) and R848 (5 ug/ml). 
LC generation  
Buffy coats were obtained from healthy blood donors (CPVE-S.Anna, Turin). Peripheral blood 
mononuclear cells enriched by Ficoll and CD14+ monocytes and BDCA1+ DCs isolated using anti- 
CD14–coated beads and human BDCA1+ DC Isolation Kit (cat. no. 130-090-506, Miltenyi). To 
obtain LC-like DCs, CD14+ monocytes were cultured for 7 days into in RPMI 1640 (cat.no. 
21875034, Thermo Fisher Scientific) with 10% FCS (cat. no. 10270-106, Thermo Fisher Scientific) 
supplemented with GM-CSF (200 ng/ml, cat.no. 300-03), IL4 (20 ng/ml, cat. no. 200-04), and 
TGFβ (10 ng/ml, cat. no. 100-21C) (all from PeproTech, London, UK) (referred to as monocyte-
derived LCs; mo-LCs). BDCA1+ DCs were differentiated for 3 days with GM-CSF (100 ng/ml) and 
TGFβ (10 ng/ml) (referred as BDCA1+ LCs). When required, LC-like DCs were matured with LPS 
(100 ng/ml, cat.no. L4391, Sigma-Aldrich) and R848 (1 g/ml, cat. no. tlrl-r848, InvivoGen, 
Toulouse, France). Cord blood was obtained from Banca del Sangue Placentare following informed 
consent. CD34+ progenitors were purified from cord blood with CD34 magnetic beads (cat. no. 130-
100-453, Miltenyi) and cultured to induce LC-like cells (referred as CD34+-LCs) in X-VIVO 15 
media (cat. no.04-448Q, Lonza, Walkersville, MD) with GM-CSF (100 ng/ml), SCF (20 ng/ml, cat. 
no. 300- 07), Flt3 (100 ng/ml, cat. no. 300-19), TNF (2.5 ng/ml, cat. no. 300-01A), and TGFβ1 (5 
ng/ml) (all from PeproTech) for 10 days. In differentiation experiments cells were cultured with 
CSF-1 (100 ng/ml, cat. no. 300-25) or GM-CSF in combination with the other cytokines for 
respectively 14 and 10 days. In some experiments, CD34+ cells were cultured with GM-CSF or 
CSF-1 in combination with the other cytokines for 12 and 22 days. Cells were differentiated in 
absence or presence of BLZ945 (0.5 M, cat. no. S7725Selleckchem, Munich, Germany) added 
after 7 days. 
 
Flow cytometry 
In vitro differentiated LCs were stained using antibodies detailed in Supplementary Table S1 and 
analyzed using BD FACSCalibur (BD Biosciences, San Josè, CA). For dermal and epidermal DCs, 
cells were stained with antibodies indicated in Supplementary Table S1. Viability was assessed 
with Viability 405/520 Fixable Dye (cat. no. 130-109-814, Miltenyi) diluted 1:100 or with 
LIVE/DEAD™ Violet Viability dye (cat. no. L34955, Thermo Fisher Scientific) diluted 1:1000. 
To minimize FcR-mediated mAb binding, cells were stained in the presence of human serum 
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containing IgG (cat. no. I2511, Sigma-Aldrich) and Tandem  Signal  Enhancer  (cat. no. 130-099-888, 
Miltenyi)  to  reduce  non-specific  binding  of  tandem  dye–conjugated  antibodies to human cells. 
Briefly cells (1x10
6
) were washed in buffer containing PBS pH 7.2, 0.5% bovine serum albumin 
(BSA), and 2 mM EDTA and stained for viability and blocking before specific antibody staining 
(incubated for 15 minutes in the dark in the refrigerator). Cells were then washed and fixed in 1% 
paraformaldehyde and acquired using MACSQuant (Miltenyi) or BD FACSVerseTM (BD 
Biosciences). Analysis was performed with FlowLogic software. 
 
 
Cell sorting for preparation of cell blocks 
Fresh PBMCs were isolated from buffy of healthy donor coat by density centrifugation using 
Ficoll-Paque gradient (GE Healthcare). For purification of monocytes populations and BDCA1
+
 
dendritic cells PBMCs were stained with the following panel of human antibodies: FITC-CD14 
(clone TUK4, cat.no. 130-113-146, Miltenyi), PE-CD56 (clone AF12-7H3, cat.no. 130-090-755, 
Miltenyi), perCP-Cy5.5–CD16 (clone 3G8, cat. no. 302030 Biolegend, San Diego, CA), PE-
VIO770–CD3 (clone REA613, cat. no. 130-113-140, Miltenyi), PE-VIO770 CD20 (clone LT20, 
cat. no. 130-113-375, Miltenyi), APC-CD303 (clone AC144, cat. no. 130-090-905, Miltenyi), APC-
CD141 (clone AD5-14H12, cat. no. 130-113-314, Miltenyi) and APC-Cy7–HLA-DR (clone L243, 
cat. no. 307618, Biolegend) and sorted using FACSAria II (BD Biosciences). Accordingly, PBMCs 
were subjected to doublets exclusion and subsequently gated on lymphocytes negative (CD3, CD19 
and CD56) and HLA-DR positive cells, finally monocytes were positively selected as CD14
+
CD16
-
 
or CD14
-
CD16
+
 whereas BDCA1
+
 were negatively selected as CD14
-
CD16
-
CD141
-
 and CD303
-
. 
Fluorescence negative controls were performed using intra-simple negative populations as 
reference. 
For cell block preparation, cell suspensions of sorted cells were centrifuged for 10 minutes at 3,000 
rpm. A solution of plasma (100 mL, kindly provided by Centro Trasfusionale, ASST Spedali Civili) 
and HemosIL RecombiPlasTin 2G (200 mL, Instrumentation Laboratory; cat. no. 0020003050; 1:2) 
were added to cell pellets, mixed until the formation of a clot, then placed into a bio-cassette (Bio-
Optica; cat. no. 07-7350). The specimen was fixed in 10% formalin (Bio-Optica; cat. no. 05-
K01004) for 1 hour followed by paraffin inclusion. 
 
LC migration assay 
Migration of mo-LCs was measured in triplicate with a transwell system (cat. no.3421, 24-well 
plates; 5.0 µm pore size; Corning Costar, NY). RPMI 1640 with 1% FCS alone, with varying doses 
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of M-CSF or IL34 (cat. no. 200-34, PeproTech) added to the lower chamber. Wells with medium 
alone were used as a control for spontaneous migration. A total of 2.5 × 105 cells in 200 µl was 
added to the upper chamber and incubated at 37°C for 4 h. In some migration experiments, cells 
were pretreated with GW2580 (1uM, cat. no. SML1047, Sigma-Aldrich) or with BLZ945 (0.5 M, 
Selleckchem) for 60 min at 37°C. For migration of BDCA1+ LC, 1.5 × 105 cells in 200 µl were 
added to the upper chamber of a transwell system (5.0 µm pore size; Corning Costar) and harvested 
after 6 h of migration towards M-CSF (50 ng/ml). Mo-LCs and BDCA1+ LCs were not enriched for 
CD207. Cells migrated into the lower chamber were harvested, concentrated to a volume of 300 µl 
of PBS, and counted by flow cytometry. Events were acquired for a fixed time of 60 s. The counts 
fell within a linear range of the control titration curves obtained by testing increasing cell 
concentrations. Values are given as the mean number of migrated cells ± SEM. 
 
Apoptosis assay 
Mo-LC were incubated in RPMI 10% FCS for 48 h in presence or absence of M-CSF or IL34 (50 
ng/ml), to evaluate their capacity of protection. Cells were washed, resuspended in Annexin Buffer, 
and evaluated for apoptosis using the annexin V-FITC apoptosis detection kit (cat. no.640914, 
Biolegend). 
 
BRAF genotyping by digital PCR 
DNA of twenty LCH cases (details in Supplementary Table S2) was extracted from sections of 
archival paraffin blocks using the QIAamp DNA FFPE Tissue Kit (cat. no. 56404, QIAGEN, 
Venlo, Netherlands). QX200 Droplet Digital PCR system (Bio-Rad, Hercules, CA) was used for 
analysis of BRAF
V600E
 mutation. ddPCR reagents were purchased from Bio-Rad and included the 
ddPCR Mutation Assay BRAF V600E FAM/HEX. BRAF
V600E
 cutaneous melanomas were included 
as positive control sample. The droplet emulsions were thermally cycled with the use of the 
following protocol: denaturation at 95°C for 10 minutes, followed by 40 cycles of 94°C for 30 
seconds and 55°C for 1 minute. After cycling, a final 10-minute hold at 98°C was applied to 
deactivate the enzyme and to stabilize the droplets. Experiments have been performed in duplicate. 
 
Gene expression profile by digital droplet PCR (ddPCR) 
Expression profile for selected targets was performed by ddPCR using the Bio-Rad QX200 ddPCR 
platform. Briefly, RNA of twelve LCH cases from skin, lung, bone and lymph node (#6, #13, #16, 
#19, #31, #35, #40, #44, #45, #47, #50, #51; see Supplementary Table S2 for details) was 
extracted from sections using RNeasy FFPE Kit (cat. no. 73504, QIAGEN). The cDNAs were 
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synthesized from total RNA using iScript gDNA Clear cDNA Synthesis Kit (cat. no. 1725035, Bio-
Rad), in a volume of 20 l, prior to droplet formation. The RNA expression for all targets was 
normalized to UBC expression. The human PrimePCR™ ddPCR™ Expression Probe Assays (Bio-
Rad) were used at a final concentration of 1X and include KRT14 dHsaCPE5192231, CSF1R 
dHsaCPE5042034, CSF-1 dHsaCPE5042260, IL-34 dHsaCPE5038840, CD207 dHsaCPE5035151 
and UBC dHsaCPE5190156. All assays were analyzed using QuantaSoft Software (Bio-Rad). 
 
Statistical Analysis 
Statistical significance was determined by using non-parametric Student t test or ANOVA followed by 
Tukey's Multiple Comparison Test, as appropriate. Results were analyzed by using GraphPad 
PRISM5.0 software.
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RESULTS 
CSF1R expression in human intraepithelial LCs and tumor-associated LCs 
We tested CSF1R expression on human tissues by using a CSF1R antibody (clone FER216) that 
recognizes CSF1R on CD16+ and CD14+ circulating monocytes (7,8) from cell block preparations 
(Supplementary Fig. S1A), CD68+ macrophages in reactive lymph nodes, and TAMs in human 
lymphomas, but that results negative on most lymphoid cells (19). In normal skin (n=2), tonsil 
(n=2), lung (n=2), esophagus (n=2), and uterine cervix (n=2), most of the CD1a+CD207+ LCs 
within the epithelium express CSF1R (Fig. 1A-C, Supplementary Fig. S1B-D). Moreover, 
macrophages in all of these tissues reacted to anti-CSF1R, as confirmed by coexpression of CD163 
(Fig. 1D), whereas no reactivity could be detected by using an isotype control (Supplementary 
Fig. S1E). 
Dermal DCs in non-inflamed normal skin are typically sparse. We could expand the analysis in 
FFPE samples containing a sizeable number of dermal immune cells by measuring cDC1s 
(CD141+), cDC2s (BDCA1/CD1c+), and the previously identified dermal CD207+ DC subset (12). 
We validated a BDCA1 antibody for FFPE using cell-block preparations of peripheral blood 
BDCA1+ DCs (Supplementary Fig. S1F). By using a set of markers including CD1a, BDCA1, 
CD207, and IRF4, we found that most dermal myeloid DCs were negative for CSF1R (Fig. 1E-G). 
This combination of antibodies confirmed the non-LC identity of the small fraction of CD207+ 
dermal cells, as suggested by others (12). CD207+ dermal DCs reacted to BDCA1 (Fig. 1H) and 
expressed IRF4, a cDC2 transcription factor (Fig. 1I) that is typically negative on LCs (Fig. 1I 
upper right). Our findings confirm a distinct cDC2 phenotype of CD207+ dermal DCs in human 
tissue. Consistent with the immunohistochemistry results, flow cytometry analysis of human 
epidermal cell suspensions revealed CSF1R expression on LCs, the latter populations defined as 
CD1a+CD207+ cells within the CD45+HLA-DR++ fraction (Fig. 2A and Supplementary Fig. S2A). 
As compared to freshly isolated LCs (Fig. 2A), a decrease in CSF1R expression on CD1a+CD207+ 
cells was observed after a 48h in epidermal CD45 enriched cell culture in the absence (14% 
reduction respect to freshly isolated cells) or, even more so, in the presence of stimulation with LPS 
and R848 (12% reduction respect to unstimulated cells) (Fig. 2B), indicating that CSF1R is 
downregulated during LC maturation. Analysis  on dermal cell suspensions revealed a low 
expression of CSF1R on the CD1a+CD207– (about 6%) and on the CD1a+CD207+ (about 2%) 
dendritic cells; in contrast, a higher percentage of CSF1R
+
 cells was observed in the CD1a– fraction, 
likely corresponding to monocytes and dermal macrophages (Supplementary Fig. S2B). 
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CD207+ tumor-associated LCs have been reported in various cutaneous cancers (20). We further 
expanded our analysis on cutaneous tumor-associated CD207+ cells. We analyzed cutaneous 
melanomas (n=9), squamous cell carcinomas (n=5) and mycoses fungoides (n=3), and found that 
CD207+CSF1R+ cells were mainly confined to the intraepithelial compartment, whereas dermal 
CD207+ cells largely lacked expression of CSF1R (Supplementary Fig. S3) and coexpressed the 
cDC2 markers IRF4 and BDCA1 (Supplementary Fig. S3B, C, E, F). 
Altogether, these findings establish that CSF1R is expressed in intraepithelial CD207+ LCs but not 
in CD207+ cDC2. This profile is similar in skin cancers. 
 
CSF1R modulation during LC differentiation and maturation 
LCs can be differentiated from monocytes or CD34+ progenitor cells. In addition, circulating 
BDCA1+ DCs are identified as an alternative source of LC precursors (12,21). LCH cells are 
presumed to arise from clonal BDCA1+ DC precursors (22). We thus evaluated CSF1R expression 
on LCs obtained from different precursors. Surface CSF1R expression was found on about 60% of 
mo-LCs (n=6), as well as on LCs obtained from CD34+ (n=4) and BDCA1+ DC precursors (n=5) 
(Fig. 3A). In line with our observation on freshly-purified primary LCs (Fig. 2B), CSF1R 
expression was significantly downregulated in mature mo-LCs, in parallel with an upregulation of 
CD83 and IRF4 expression (Fig. 3B). 
Nodal LC-like cells are undetectable in unstimulated lymph nodes, but they are easily identifiable 
within the lymphatic sinuses and in expanded T-cell nodules of the paracortex in the so-called 
dermatopathic lymphadenitis. This is a condition in which, following proinflammatory stimuli, LCs 
migrate to draining lymph nodes and undergo maturation. In the paracortex of human lymph nodes, 
the LC-like population has been referred by pathologists to as interdigitating dendritic cells (IDCs) 
and displays the S100+CD1a+CD207+/– phenotype. Expectedly, IDCs also coexpress a set of 
maturation markers such as CD80, CD83, CD208, and CCR7. By evaluating CSF1R expression on 
ten cases of dermatopathic lymphadenitis, we found CSF1R expression on macrophages in various 
nodal compartments (Supplementary Fig. S4A), in line with published data (19). On the contrary, 
IDCs of the paracortex largely lacked CSF1R expression (Fig. 3C, D), although it was possible to 
identify a small population of CSF1R+CD207+ within the nodal lymphatic sinuses (Fig. 3D-F, 
Supplementary Fig. S4B-E). 
The notion that IDCs in the paracortex are mainly LC-derived has been challenged, particularly in 
the mouse system. Cells of non-LC identity and likely corresponding to cDC2s have been identified 
in the T cell paracortex (23). By analysis of dermatopathic lymphadenitis (n=4), 
CSF1R+CD207+ LCs within the nodal lymphatic sinuses lacked expression of BDCA1 and IRF4 
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(Fig. 3F and Supplementary Fig. S4B, C) and lacked the maturation markers CD83 and CD208 
(Supplementary Fig. S4D, E). On the contrary, most IDCs in the paracortical T-cell nodules 
expressed the transcription factor IRF4 (Fig. 3G, H). Further, we could identify two main IDC 
subpopulations showing a distinct localization (Fig. 3H and Supplementary Fig. S4F, G). Cells in 
the outer paracortex that coexpressed BDCA1 and IRF4, and expressed CD83 and CD208, likely 
correspond to mature cDC2 (Fig. 3H, Supplementary Fig. S4G and H). Nodal cDC2s can derive 
from circulating cDC2s via high endothelial venules or from migrating dermal cDC2s, including the 
CD207+ minor subset. The second subpopulation was mainly located in the inner paracortex and 
included CD207+BDCA1–IRF4+ cells (Fig. 3H and Supplementary Fig. S4F, G) coexpressing 
CD208 (Supplementary Fig. S4G), likely corresponding to mature LCs; accordingly, we could 
demonstrate  IRF4 induction upon in vitro maturation of LC (Fig. 3B). Of note, mouse dermal DCs 
migrate in the outer paracortex, whereas epidermal LCs are mainly found in the inner paracortical 
area (24). With some heterogeneity from case to case, we uncovered a third minor fraction of the 
BDCA1+ in the paracortex coexpressing CD207 (Supplementary Fig. S4G black arrow); a similar 
population was also found within the nodal sinuses, likely representing migrating dermal CD207+ 
cDC2s (Supplementary Fig. S4I). Altogether, these findings suggest that CSF1R expression is 
tightly associated to LC differentiation but is lost upon maturation. Immature CSF1R+LCs are 
confined to the nodal sinuses, whereas their maturation is coupled with loss of CSF1R. Moreover, a 
dermal cDC2 identity of a fraction of CSF1R– IDCs should be considered. 
 
CSF1R inhibition impairs LC migration and differentiation. 
CSF1R signaling is relevant during macrophage proliferation and differentiation (25). CSF1R 
blockade in tumor-bearing mice and cancer patients results in depletion and molecular 
reprogramming of tumor associated-macrophages (26). CSF1R-induced cell migration plays an 
important role in macrophage trafficking to tumor tissues (27). We examined the ability of mo-LCs 
to migrate towards CSF-1 and IL34 (n=4). CSF-1 showed a significant chemotactic effect at 50 
ng/ml that is maintained at 200 ng/ml (Fig. 4A, left panel and Supplementary Fig. S5A). No effect 
of IL34 on mo-LCs migration was observed (Fig. 4A, left panel and Supplementary Fig. S5A). 
The migration toward CSF-1 diminished following treatment with the c-FMS/CSF1R kinase 
inhibitors GW2580 and BLZ945 (Fig. 4A, middle panel). The chemotactic effect of CSF-1 was also 
demonstrated in BDCA1+ DC-derived LCs (Fig. 4A, right panel). Since IL34 and CSF-1 have been 
shown to promote cell survival (28), we investigated the role of these two cytokines in mo-LC 
viability (n=4). No significant differences were observed in the percentage of live mo-LCs 
following IL34 and CSF-1 treatment compared to untreated cells (Supplementary Fig. S5B). Data 
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on the role of CSF-1 on the differentiation of CD207+ cells from precursors are largely missing in 
the literature. We generated LCs from CD34+ progenitor (n=3) cells in presence of the standard 
cytokine cocktail (SCF, Flt3L, TNF, and TGF1) in combination with CSF-1 and compared to 
GM-CSF (Fig. 4B). CSF-1 induced a consistent differentiation in CD1a+CD207+ cells (88.3±2.7%) 
and the blockade of the CSF1/CSF1R signaling with BLZ945 significantly reduced differentiation 
(53±6.7%) of CD1a+CD207+ cells (p = 0.0083). The percentage of CD1a+CD207+ cells recovered 
from CSF-1 culture was higher than that obtained from GM-CSF culture, and the latter was not 
affected by BLZ945 (Fig. 4B, right panel; p= 0.83). Based on the different kinetics of 
differentiation between the two experimental conditions (29) (30), the analysis was performed at 10 
and 14 days of culture, respectively for GM-CSF and CSF1. However, the BLZ945 effect on CSF-1 
but not GM-CSF culture was also confirmed when cells were treated for the same length of time (12 
and 22 days) (Supplementary Fig. S6). The cell recovery yield was higher for GM-CSF culture 
compared with CSF1. Specifically, starting from 0.2x106 CD34+ cells the absolute number of viable 
cells recovered from GM-CSF culture was 11.2 ± 4.8 x 106 (56 ± 24 fold increase), but no 
differences were observed after BLZ945 treatment (p= 0.975). The yield of cells from CSF-1 
culture was 3.3 ± 0.8 x 106 (17 ± 3.9 fold increase) but was significantly reduced by the addition of 
BLZ945 (p= 0.039). 
These results indicate that CSF-1 regulates LC migration and may induce LC differentiation from 
CD34+ precursors. 
 
CSF1R expression in neoplastic cells and TAMs in Langerhans cells histiocytosis. 
Clonally transformed LCs are found in LCH (1). LCH biopsies show tissue infiltration of 
CD1a+CD207+S100+ LCs on a background of inflammatory cells including eosinophils and 
macrophages. We tested the expression of CSF1R in a large retrospective cohort of LCH biopsies 
(n=54) including 9 multisystemic disease (Table 1 and details in Supplementary Table S2). Two 
representative cases are illustrated in Figure 5. LCH diagnosis was defined based on the 
morphology and phenotype of LCH cells using CD1a, CD207, and S100 (Fig. 5A-T). In  addition, 
LCH cases were tested for BRAF
V600E
 mutation by immunohistochemistry (Fig. 5E, J, O, T; 
Supplementary Table S2 and Supplementary Fig. S7) and droplet digital PCR (Supplementary 
Table S2 and Supplementary Fig. S7E, J, O). We found that CSF1R was expressed in all cases 
(Supplementary Table S2). The stain was observed in the cytoplasm as well as on the cell 
membrane (n= 33/54; 61,1% of LCH cases) (Fig. 5I, Supplementary Fig. S7C, H, M and 
Supplementary Table S2). CSF1R expression on tissue LCH cells was confirmed in serial sections 
(Supplementary Fig. S7) and by its colocalization with cytoplasmic anti-VE1, recognizing the 
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BRAFV600E mutant (Fig. 5U-W). We could confirm CSF1R reactivity also by using a second 
antibody (clone SP211, rabbit monoclonal) recognizing a portion of the intracellular domain of 
CSF1R (Supplementary Fig. S8). In addition to neoplastic cells, anti-CSF1R also reacted with 
surrounding CD163+ tumor-associated macrophages (Fig. 5X). 
Based on the down-modulation of CSF1R in matured LCs, we tested the phenotype of neoplastic 
LCs in a set of LCH cases (n=9). Most neoplastic LCH cells regularly display an immature 
phenotype, as previously reported (31), largely lacking expression for CD83, CD208, and CCR7 
(Supplementary Fig. S7P–R). Findings suggest that circulating LCH cells display a cDC2 
phenotype and likely represent immediate precursors of transformed LC cells (22). Staining for 
BDCA1 and CD207 confirm a highly frequent (n= 43/43; 100%) and diffuse expression of BDCA1 
on tissue CD207+ LCH cells (Supplementary Fig. S7S–T). Coexpression of IRF4 with CD207 was 
frequently observed (n= 35/46; 76,1%), although it was highly heterogeneous in its distribution (Fig. 
5Y and Supplementary Table S2). This hybrid phenotype indicates that, in more than two thirds of 
the cases, tissue LCH cells are cDC2-derived. However, CSF1R expression in LCH is stably retained 
irrespectively of their phenotype. In addition, CSF1R expression is also found in surrounding TAMs, 
indicating that both cell types might be targeted by CSF1R blockade. 
 
CSF-1 transcript and phospho-p44/42 expression in LCH tissues. 
We next analyzed the expression of CSF1, CSF1R, and IL34 in a group of twelve LCH cases, with 
available archival material including skin and extra-cutaneous LCH, by digital droplet PCR. Keratin 
14 (KRT14) and CD207 were used as markers of epidermal keratinocytes and neoplastic LCH-
cells. Accordingly, KRT14 transcript expression was limited to skin biopsies, whereas CD207 
expression was often found to be comparable in skin and extra-cutaneous LCH. We could detect 
expression of CSF-1 (10/12; 83.3%) and CSF1R (12/12; 100%) in the large majority of the LCH 
cases (Fig. 6A, B), whereas IL34 expression was largely absent. CSF1R engagement by CSF-1 
results in downstream activation of the MAPK pathway. Similar to BRAF-mutated cases (n=8) 
(Supplementary Fig. S9), in BRAF wild-type cases (n=6), CSF1R+ neoplastic cells frequently 
stained for anti–phospho-p44/42 MAPK (Thr202/Tyr204) as demonstrated in serial sections; anti–
phospho-p44/42 was also detected in some tumor-associated macrophages (Fig. 6C-H). These 
findings suggest MAPK pathway activation also occurs in the absence of BRAF mutations and 
might partially rely on CSF1R signaling. 
 
DISCUSSION 
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LCs  are specialized dendritic cells located within the epithelial surface. During inflammation, LCs 
can arise from CD34+ progenitors, classical monocytes, and BDCA1+ blood cDC2s (9,32). Data 
suggest that murine LC development is dependent on CSF1R signaling (10,11,33), but limited data 
are available on its expression and function in human LCs. We report here that CSF1R was 
expressed by human LCs and was involved in LC migration towards CSF1. CSF1R stained LCH 
cells and TAMs, whereas CSF-1 was abundantly produced in neoplastic tissues. CSF1R was 
expressed in normal LCs, tumor-associated LCs infiltrating skin cancer, and in nodal LCs within 
the lymphatic sinuses of dermatopathic lymphadenitis. On the contrary, most dermal myeloid DCs, 
including a minor subset of CD207+, lacked CSF1R. We demonstrated surface CSF1R on LCs 
isolated from human skin and on immature LCs in vitro generated from CD34+ progenitors, CD14+ 
monocytes, and BDCA1+ cells, by using published protocols (32,34). 
 
The role of tumor-associated LCs has been partially investigated in skin cancer (35). Based on our 
study, CSF1-producing tumors might modulate the LC contexture at different sites, particularly in 
lymph nodes draining skin cancer. Similar to TAMs (7,36), LCs might represent a relevant cell 
target during therapeutic CSF1R blockade. This hypothesis is further strengthened by our 
observation that CSF1R signaling was involved in LC expansion from CD34+ precursors, 
suggesting that CSF1R blockade could result in a more dramatic and stable defect of the LC pool in 
these patients. We found that the presence of CSF-1 during CD34+ differentiation gave rise to a 
higher fraction of CD1a+CD207+ LCs that was reduced by CSF1R blockade. Our study corroborates 
previous observations (29,37) on the role of CSF-1 on the LC differentiation. We have not 
monitored LC precursors at various stage of differentiation during CSF-1 culture and CSF1R 
blockade. However, it is known that CD1a–CD14+CSF1R+ LC precursors require exogenous TGF 
(38) In addition, monocyte and DC progenitor cells express CSF1R (13). The effect of CSF-1 and 
CSF1R-blockage in LCs will certainly benefit from additional preclinical modelling and clinical 
monitoring on cancer patients. 
 
After receiving local signal, LCs migrate to draining lymph nodes. A set of proinflammatory stimuli 
and chemokines are required for LC migration to the nodal paracortex in form of LC-derived 
S100+CD1a+CD207+/– IDCs. We found that CSF1R is expressed by immature LCs confined to the 
nodal sinuses, but it is rapidly downregulated upon maturation; in line with this observation, 
downregulation of CSF1R was documented in DCs exposed to TNF (39). In contrast with LCs, 
most IDCs lacked expression of CSF1R. Lack of CSF1R on IDCs could be a function of their 
mature phenotype, as demonstrated in this study. Alternatively, a non-LC identity has been 
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proposed for IDCs (23), and other studies have demonstrated a cDC2 phenotype of IDCs (23). We 
found that a fraction of IDCs, particularly those located in the outer paracortex, mainly display a 
mature cDC2 phenotype, whereas IDCs in the inner paracortex more likely correspond to mature 
LCs. 
 
In the current study, the expression of CSF1R in LCH biopsies was demonstrated by using two 
antibodies recognizing different CSF1R domains, and CSF1R reactivity was detected on LCH cells 
and TAMs. In BRAF–wild-type cases, CSF1R+ cells coexpressed phospho-p44/42, suggesting 
CSF1R-dependent persistent activation of the MAPK pathway (28). Subcellular distribution of 
CSF1R in LCH cells included cytoplasmic and membrane localization. The observed subcellular 
heterogeneity may be consistent with the receptor compartmentalization during activation and 
subsequent degradation (40,41). Alternatively, genomic abnormalities at the CSF1R locus or post-
transcriptional modification occurring in LCH cells, as observed in other cancers, might explain this 
variability (42). 
 
IL34 was identified as an alternative ligand of CSF1R showing overlapping functions with CSF-1 
with respect to myeloid lineage differentiation, proliferation, and survival (43). Of note, we found 
that CSF-1 was a potent chemoattractant for LCs, whereas IL34 showed no activity. These results 
support the notion that the two cytokines are partially redundant, as demonstrated by their different 
ability to induce morphological changes and cytokines production in macrophages (44). Previous 
data confirms the role of CSF1R signaling in the chemotaxis of mononuclear phagocytes (45). CSF-
1 is highly expressed in carcinomas and sarcomas from different primary sites (46), whereas no data 
are available on LCH biopsies. We found that in contrast with IL34, CSF-1 is abundantly produced 
in cutaneous and extra-cutaneous LCH tissue. This finding might explain the high serum 
concentration of CSF-1 in patients with multisystemic LCH (16,17) and suggests that CSF1R+ LCH 
cells are  recruited to neoplastic tissues by high local amounts of CSF1, as also reported in diffuse-
type Tenosynovial Giant Cell Tumor (47). 
 
Reports on systemic LCH indicate a hematopoietic origin of LCH cells. Clonal circulating 
precursors can be detected in form of CD34+ progenitors, monocytes and cDC2s (5,6), likely 
representing immediate precursors of LCH cells (22). High serum concentrations of TGF and 
CSF-1 have been found in LCH patients, suggesting their contribution in the differentiation of 
tissue-infiltrating neoplastic LCs from hematopoietic precursors (48). Transcriptomic studies 
revealed a monocyte-LC signature for LCH cells driven by JAG2-mediated activation of Notch 
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(49). We observed a hybrid phenotype of BRAFV600E LCH cells, with cDC2 markers (BDCA1+  and 
IRF4+) admixed to LC markers (CD1a, CD207, and CSF1R) indicating that a partial LC 
commitment of cDC2 circulating precursors might also occur. Since CSF1R is required for terminal 
LC differentiation from CD34 precursors, as shown in the current study, we propose that CSF1R 
blockade might improve the LCH evolution. 
 
In conclusion, although we recognize that additional data on fresh LCH cells are required to 
confirm our findings, we propose that LCH cases (and likely other LC/macrophage derived 
neoplasms) might derive benefit from CSF1R blockade, a hypothesis suggested previously on 
preliminary findings (9). The relevance of this recommendation is further strengthened by the 
identification of activating CSF1R mutations in histiocytic neoplasm, with mutated tumor cells 
resulting sensitive to CSF1R blockade (18,50). We envisage a synergistic clinical benefit by 
targeting tissue LCH cells (and their circulating precursors) and TAMs. Of note, CSF1R expression 
is also detected in the BRAFV600E mutated forms of LCH, a candidate group for BRAF inhibitors 
(51,52) as a treatment option (53).  However, the clinical benefit of  MAPK inhibition in these 
patients is transient with frequent relapse (54-56), suggesting that additional treatment options are 
required for life-threatening LCH. Responders to CSF1R blockade will be likely enriched in the 
BRAF wild-type subgroup. However, concomitant or sequential combination of BRAF- and 
CSF1R-blockade could be effective in BRAFV600E LCH, as observed in preclinical models of 
melanomas (57,58), although it remains to be established how these compounds cooperate in LCH. 
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Table 1. Summary of LCH cases analyzed 
 
 
Site of LCH 
lesion 
Number 
of cases 
Median age 
(year range) 
gender 
(M;F) 
BRAF 
V600E
 
(%) 
 
MD (%) 
Skin 16 15,4 11;5 8 (36,4) 6 (27,3) 
Bone 20 17 13;7 8 (40) 0 (0) 
Soft Tissue 5 15 1;4 2 (40) 1 (20) 
Lung 5 28,8 1;4 4 (80) 0 (0) 
Lymph node 4 41,6 2;2 0 (0) 1 (25) 
Other 
localization 
4 17,25 2;2 3 (75) 1 (25) 
 
TOTAL 
 
54 
22,5 
(1 DAY-79 YEARS) 
 
30;24 
 
25 (41,7) 
 
9 (15) 
 
Legend: MD= multisystemic disease
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FIGURE LEGENDS 
 
Figure 1: CSF1R recognizes CD207+ LCs but not dermal CD207+ DCs. Sections are from 
reactive human lung (A), esophagus (B), and skin (C-I) and stained as labeled. CD207+ LCs in 
bronchus epithelium (A), esophagus mucosa (B) as well as normal skin (C) coexpress CSF1R. 
Dermal CSF1R+ cells largely correspond to CD163+ macrophages (D). CSF1R is mainly negative in 
CD207+ (E), CD1a+ (F), and BDCA1+ (G) dermal DCs. Dermal CD207+ DCs are mostly BDCA1+ 
(H) and IRF4+ (I). Green traces separate epidermis from dermis. Sections are counterstained with 
hematoxylin. Original Magnification: 200x (A, B, F; scale bar = 100 microns), 400x (C, D, G, I; 
scale bar = 50 microns) and 600x (E, H; scale bar 33 microns). Insets were obtained by single cell 
resizing of a 200x magnification. Micro-photographs were taken using the acquisition software 
cellSens (Olympus) and DP-73 Olympus digital camera mounted on the Olympus BX60 
microscope. 
 
Figure 2: Expression of CSF1R on human epidermal subpopulations. (A) Single cell 
suspensions from human epidermis were processed for flow cytometry analysis. Gating strategy 
used to exclude cell debris, doublets and dead cells is presented in the panel. CSF1R surface 
expression was analyzed in the CD1a+CD207+ fraction within the CD45+ HLA-DR++ population 
(red). In parallel, expression of CSF1R was verified in CD45– (pink) and CD45+ (yellow) cells. 
Fluorescence minus one (FMO) controls for the antibodies are shown. Data from one representative 
experiment are presented (n = 5). (B) CD45+ epidermal cells were untreated or stimulated for 48 h 
with LPS (1 µg/ml) and R848 (5 µg/ml) and evaluated for CSF1R and CD83 expression by flow 
cytometry analysis, using the same gating strategy of panel A (one representative experiment out of 
four is shown). The values in the bottom graph show the average percentage of CSF1R
+
 cells ± 
SEM from 4 independent experiments. * p < 0.05 vs. untreated cells by Student t test. 
 
Figure 3: CSF1R modulation during DC differentiation and maturation. (A) LCs differentiated 
from human CD14+ cells (mo-LCs), BDCA1+ cells, and CD34+ cells were evaluated for the 
expression of CSF1R in the CD1a+CD207+ fraction. Controls for CSF1R (fluorescence minus one, 
FMO) are shown. Representative flow cytometry analysis (top) and summary results (bottom; mean 
± SEM) of respectively 6 (mo-LCs), 5 (BDCA1+ LCs) and 4 (CD34+ LCs) experiments are shown. 
(B) mo-LC were untreated or stimulated for 48 h with LPS (100 ng/ml) and R848 (1 ug/ml) and 
evaluated for CSF1R, CD83, and IRF4 expression by FACS analysis (one representative 
experiment is shown). FMO controls for all antibodies are shown. The values in the bottom graph 
show the average percentage of CSF1R
+
 cells ± SEM evaluated in 4 independent experiments. * 
p<0.05 vs. untreated LCs by Student t test. Sections are from three human skin-draining lymph 
nodes with dermatopathic reaction and stained as labeled. CSF1R
+
 cells are predominantly located 
at the periphery of dermatopathic CD1a+ nodules (C) and within the lymphatic sinus coexpressing 
CD207 (D black arrows, E) but not IRF4 (F); sinuses are lined by PDPN+ endothelial cells (E). 
Paracortical IDC nodules are composed by mature CD208+CD207+ IDC coexpressing IRF4 (G). 
The two IDC populations include CD207+/–BDCA1+ cells mainly in the outer paracortex and 
CD207+BDCA1– in the inner paracortex (H); both populations express IRF4 (H). Sections are 
counterstained with hematoxylin. Original Magnification: 100x (C, D; scale bar = 200 micron), 
200x (E, H: scale bar = 100 microns) and 600x (F, G; scale bar = 33 micron). 
 
Figure 4. Effect of CSF1R ligands on LCs. (A) mo-LCs (2.5 × 105) were seeded in the upper 
compartments of a 24-well Transwell cell culture chamber; CSF-1 or IL34 (50 ng/ml) were added 
to the lower compartments. Cells that migrated to the lower compartments after 4 h incubation were 
counted by flow cytometry (left panel). Mo-LCs were preincubated with GW2580 (1uM) or 
BLZ945 (0.5 µM) for 1 h at 37°C. Thereafter, chemotaxis was measured in response to CSF-1 (mid 
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panel). The chemotaxis of BDCA1+ LCs was measured in response to CSF-1 (50ng/ml) after 6 h 
incubation (right panel). Assays were performed in triplicate. Mean value ± SEM of 4 independent 
experiments for mo-LC and of 3 independent experiments for BDCA1+ LCs are shown. * p<0.05 
vs. untreated LCs; # p<0.05 vs. CSF1-migrated LCs by one-way ANOVA followed by Tukey's 
Multiple Comparison Test or by Student t test as appropriate. (B) LCs were differentiated from 
CD34+ cells in presence of CSF-1 or GM-CSF for 14 and 10 days, respectively.  In parallel, cells 
were treated with BLZ945 (0.5 uM) for the indicated culture conditions. One representative 
experiment of the expression of CD1a and CD207 is shown as a flow cytometry dot plot. 
Fluorescence minus one (FMO) controls for antibodies are shown. The average percentage of 
CD1a-/CD207–, CD1a+/CD207– and CD1a+/CD207+ cells within CSF1-differentiated LCs and GM-
CSF-differentiated LCs in presence or absence of BLZ945 is reported (mean value ± SEM of  3 
independent experiments) * p<0.05 vs. untreated LCs by Student t test. 
 
Figure 5: CSF1R expression in LCH. Sections are from 5 human LHC and stained as labeled. 
Phenotypical characterization of two LCH (A-T), BRAFV600 (A-J) and BRAFV600E (K-T) as defined 
by VE1 stain and digital PCR. Neoplastic cells, recognized by double stain for VE1 and CD207 (U) 
coexpress CSF1R (V, W). In the LCH microenvironment, CSF1R is also expressed on CD163+ 
macrophages (X). A representative LCH case showing coexpression of CD207+ and IRF4+ in 
neoplastic cells is reported in Y. Sections are counterstained with hematoxylin. Original 
Magnification: 40x (A-E, K-O; scale bar = 500 micron), 400x (F-J, P-T, U, V, X, Y; scale bar = 50 
microns) and 600x (W; scale bar = 33 µm). 
 
Figure 6: CSF1R, CSF1, IL34 mRNA, and phospho-p44/42 MAPK (Thr202/Tyr204) in LCH 
tissue. The graphs illustrate the ddPCR-based detection of mRNA of KRT14, CD207, and CSF1R 
(A), as well as CSF-1 and IL34 (B) in 12 LCH samples from cutaneous (n = 7) and extracutaneous 
(n = 5) sites. All samples were normalized to UBC mRNA expression. Undetectable mRNA are 
reported as 0.01. Sections are from two BRAF wild-type LCH cases (#8 C-E, #36 F-H) and stained 
as labelled. On serial sections, LCH cells stained for anti–phospho-p44/42 MAPK (Thr202/Tyr204) 
(C, D and F, G); the latter marker is also observed in a fraction of surrounding tumor-associated 
macrophages (E and H) as documented by staining for CD163. Sections are counterstained with 
hematoxylin. Original Magnification: 200x (C, D, F and G; scale bar 100 µm) and 400x (E and H; 
scale bar 50 µm). 
 






